Extended-Spectrum β-Lactamase and Multidrug Resistance in Urinary Sepsis Patients Admitted to the Intensive Care Unit

Bumjoon Kim, M.D.*, Sung Gyun Kim, M.D.†, Seung Soon Lee, M.D.‡, Tae Seok Kim, M.D‡, Yong Il Hwang, M.D.*, Seung Hun Jang, M.D.*, Joo Hee Kim, M.D.*, Ki-Suck Jung, M.D.*, and Sunghoon Park, M.D.*

*Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, †Division of Nephrology, Department of Internal Medicine, ‡Division of Infectious disease, Department of Internal Medicine, 3Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea

Background: The role of extended-spectrum β-lactamase (ESBL)-producing or multidrug-resistant (MDR) organisms in patients with sepsis secondary to urinary tract infection (UTI) has not been investigated extensively in the intensive care unit (ICU) setting.

Methods: Patients with UTI sepsis admitted to the ICU were retrospectively enrolled in this study (January 2009-December 2012). We investigated the impact of ESBL-producing and ESBL-negative MDR organisms on hospital outcome.

Results: In total, 94 patients were enrolled (median age, 73.0 years; female, 81.9%), and ESBL-producing and ESBL-negative MDR organisms accounted for 20.2% (n = 19) and 30.9% (n = 29), respectively. Both patients with ESBL-producing and ESBL-negative MDR organisms were more likely to experience a delay in adequate antibiotic therapy than those with non-ESBL/non-MDR organisms (p < 0.001 and p = 0.032, respectively). However, only patients with ESBL-producing organisms showed a higher mortality rate (ESBL vs. ESBL-negative MDR vs. non-ESBL/non-MDR, 31.6% vs. 10.3%.vs. 10.9%, respectively). In multivariate analyses, ESBL production was significantly associated with hospital mortality (odds ratio, 11.547; 95% confidence interval, 1.047-127.373), and prior admission was a significant predictor of ESBL production.

Conclusion: Although both ESBL-producing and ESBL-negative MDR organisms are associated with delayed administration of appropriate antibiotics, only ESBL production is a significant predictor of hospital mortality among patients with UTI sepsis in the ICU setting.

Key Words: beta-lactamase; drug resistance, multiple; intensive care units; sepsis; urinary tract infections.

Introduction

Urinary tract infection (UTI) is one of the most common infectious diseases in both community and hospital settings and may be responsible for 20-30% of all cases of sepsis.[1,2] The frequency of infections by drug-resistant pathogens is increasing, and some patient groups with UTIs still have high mortality rates.[3]

Multidrug resistance (MDR) is an increasing concern worldwide, and extended-spectrum β-lactamase (ESBL) is one of the most important plasmid-mediated β-lactamases produced by drug-resistant enterobacteria. Recently, the prevalence of ESBL producers in UTIs caused by Escherichia coli and Klebsiella pneumoniae was reported to be > 50% in several Asian countries.[4,5] Although MDR and ESBL productions are associated with a delay in the administration of appropriate antibiotics in patients with UTI or bacteremia, data on their associations with hospital mortality are conflicting.[6-9] However, the severity of illness is usually high, and early administration of appropriate antibiotics is important for patients with sepsis admitted to the intensive care...
unit (ICU). Additionally, antibiotic treatment options for MDR or ESBL-producing organisms are limited. Therefore, although mortality is relatively lower in patients with urinary-source compared with non-urinary-source sepsis,[10,11] UTI sepsis caused by MDR organisms may be important among patients admitted to the ICU.

To date, many authors have investigated the prevalence of and risk factors for MDR or ESBL in patients with UTI.[6,7,12,13] However, data on the impact of ESBL or ESBL-negative MDR on hospital outcome in the ICU setting are limited. Therefore, in this study, we investigated the impact of ESBL or ESBL-negative MDR on hospital mortality in UTI sepsis patients admitted to the ICU.

Materials and Methods

1) Study design

This was a retrospective cohort study conducted in a 16-bed medical ICU at Hallym University Sacred Heart Hospital (an 800-bed tertiary university hospital) between January 2009 and December 2012. Adult patients (≥ 18 years) diagnosed with UTI sepsis and admitted to the ICU were included in the study. The following were used as exclusion criteria: no organisms identified or polymicrobial infection, no outcome data due to transfer to another hospital, do-not-resuscitate status or treatment restrictions, cardiopulmonary resuscitation at an emergency department or ICU admission, or an immunocompromised status (e.g., inherited genetic diseases, acquired diseases [e.g., HIV, solid or hematologic cancer], and medications [e.g., steroid, chemotherapy, radiotherapy, other immunosuppressant agents]). However, patients were eligible when their cancers had been in complete remission for > 6 months or when they were being treated with a low-dose steroid (i.e., ≤ 10 mg/day prednisolone or equivalent).

2) Data collection

We collected the following data: age, gender, prior history, co-morbid illnesses, Charlson comorbidity index, and Simplified Acute Physiology Score (SAPS) II at ICU admission. Laboratory data, including routine chemistry and cardiac markers, were also collected. We evaluated the inappropriateness of empirical antibiotics and measured time intervals (i.e., hour) from ICU admission to the treatment with appropriate antibiotics for all patients that were enrolled. We investigated the ICU and hospital mortality rates, as well as the length of hospital stay (i.e., from ICU admission to hospital discharge). The Institutional Review Board at Hallym University Sacred Heart Hospital approved this study (IRB No. 2014-1134), and the requirement for informed consent was waived due to the retrospective nature of the study.

3) Definitions

UTI sepsis was defined by the International Sepsis Forum Consensus Conference Definitions of Infection in the ICU.[11,14] For noncatheterized patients, at least two of the following criteria were required: fever (> 38ºC); urgency; localized pain or tenderness at the involved site; and any of the following: pyuria, bacteriuria, purulent discharge from the affected site, hematuria, positive Gram stain, organism isolated from urine culture (> 10^5 colony-forming units [CFU]/ml), or radiologic evidence of infection (e.g., hydronephrosis, stenosis, renal abscess, etc). Catheterized patients were required to meet one of the following criteria: localizing signs or symptoms compatible with UTI, a positive blood culture, or imaging that supported a urinary source, in addition to a positive urine culture (> 10^5 CFU/ml).

Sepsis was defined as the probable or documented presence of infection in addition to systemic manifestations of infection. Severe sepsis was defined as sepsis plus sepsis-induced organ dysfunction or tissue hypoperfusion. Septic shock was defined as severe sepsis with hypotension despite adequate fluid resuscitation.[15] Community-acquired infection was defined as a positive urine culture obtained at the time of hospital admission or < 48 hours after hospitalization; however, an infection was classified as healthcare-associated if a patient met any of the healthcare-risk factors as reported by Friedman et al.[16] Hospital-acquired infections were defined as a positive culture obtained > 48 hours after hospitalization.

4) Microbiological evaluation and antibiotic treatments

Species identification and antimicrobial susceptibility tests were performed using the MicroScan Neg Breakpoint Combo Panel Type 42 (Siemens Healthcare Diagnostics, Inc., West Sacramento, CA, USA) in accordance with the manufacturer’s instructions. The production of ESBL was determined by a double-disk synergy test as described by the Clinical and Laboratory Standards Institute.[17] A pathogen was defined as MDR when it was resistant to at least three classes of antibiotics.[13]

In terms of antibiotic treatments, patients were treated empirically according to the treatment guidelines at ICU admission.[14,18] However, as soon as the causal pathogen was identified, antibiotics were adjusted according to the susceptibility test results.
Empirical antibiotics were considered appropriate when isolated organisms were susceptible to the antibiotics.

5) Outcome measures
The primary outcome was the relationship between ESBL-producing or ESBL-negative MDR organisms and hospital mortality in patients with UTI sepsis in the ICU setting. The secondary outcomes were the initial rates of inappropriate antibiotic administration for ESBL-producing or ESBL-negative MDR organisms and several risk factors for ESBL production in patients with UTI sepsis.

6) Statistical analysis
Data are presented as median (interquartile range, IQRs) for continuous data and percentage for categorical data. For comparisons between two groups, the Mann-Whitney U test was used for continuous data, while the chi-square or Fisher’s exact test was used for categorical data. Multivariate logistic regression analyses were performed using covariates with \( p < 0.05 \) in the univariate analyses. The Kaplan-Meier method with the log-rank test was also performed. All reported \( p \) values were two-sided, and \( p < 0.05 \) was deemed to indicate statistical significance. All analyses were conducted using the SPSS statistical software (IBM SPSS Statistics version 21, Standard for Medical Network, Armonk, NY, USA).

Results

1) Study population
In total, 125 patients with UTI sepsis, severe sepsis, or septic shock were initially screened. Of these, 94 were enrolled in the present study (Fig. 1). The mean age was 73.0 years (65.0-81.0 years), and 81.9% of the patients were female (Table 1). Fifty-five patients (58.5%) had community-acquired infections, 25 patients had healthcare-associated infections, and 14 had hospital-acquired infections. Forty-nine patients (52.1%) were bed-ridden, and 19 (20.2%) had a history of prior UTI within the last year. Thirty patients (31.9%) had structural abnormalities or lesions in the urinary tract. Eight patients (8.5%) underwent percutaneous nephrostomy, 65 (69.1%) received vasopressors, and 29 (30.9%) were treated with mechanical ventilation.

2) Microbiological data
Among the causal organisms, \( E. \) coli was the most common pathogen (n = 66, 70.2%); five patients had Gram-positive infections, and one patient had a fungal infection (Table 2). ESBL-producing and ESBL-negative MDR organisms accounted for 20.2% (n = 19) and 30.9% (n = 29), respectively, and one patient had a carbapenem-resistant organism. Among the \( E. \) coli isolates, 21.2% were ESBL producers and 31.8% were ESBL-negative MDR organisms. The ESBL rates of \( P. \) mirabilis and \( K. \) pneumoniae were 42.9% (3/7) and 33.3% (2/6), respectively. The rate of bacteremia was 63.2%, 72.4%, and 69.6% in patients with ESBL-producing, ESBL-negative MDR, and non-ESBL/non-MDR organisms, respectively (\( p = 0.791 \)).

3) Comparison of inappropriate antibiotic administration
In this study, \( \beta \)-lactams (n = 27) and quinolones (n = 28) were...
Table 2. Causal organisms of UTI sepsis

<table>
<thead>
<tr>
<th>Organisms</th>
<th>N (%)</th>
<th>Bacteremia</th>
<th>ESBL</th>
<th>MDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Escherichia coli</td>
<td>66 (70.2%)</td>
<td>46 (69.7%)</td>
<td>14 (21.2%)</td>
<td>21 (31.8%)</td>
</tr>
<tr>
<td>Proteus mirabilis</td>
<td>7 (7.4%)</td>
<td>7 (100.0%)</td>
<td>3 (42.9%)</td>
<td>1 (14.3%)</td>
</tr>
<tr>
<td>Klebsiella pneumoniae</td>
<td>6 (6.4%)</td>
<td>4 (66.7%)</td>
<td>2 (33.3%)</td>
<td>1 (16.7%)</td>
</tr>
<tr>
<td>Enterobacter aerogenes</td>
<td>4 (4.3%)</td>
<td>1 (25.0%)</td>
<td>0 (0.0%)</td>
<td>1 (25.0%)</td>
</tr>
<tr>
<td>Enterobacter cloacae</td>
<td>1 (1.1%)</td>
<td>1 (100.0%)</td>
<td>0 (0.0%)</td>
<td>1 (100.0%)</td>
</tr>
<tr>
<td>Enterococcus faecalis</td>
<td>3 (3.2%)</td>
<td>1 (33.3%)</td>
<td>0 (0.0%)</td>
<td>2 (66.7%)</td>
</tr>
<tr>
<td>Streptococcus agalatiae</td>
<td>1 (1.1%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Viridans streptococcus</td>
<td>1 (1.1%)</td>
<td>1 (100.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Citrobacter freundii</td>
<td>1 (1.1%)</td>
<td>1 (100.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Acinetobacter baumannii</td>
<td>1 (1.1%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>1 (1.1%)</td>
<td>1 (100.0%)</td>
<td>0 (0.0%)</td>
<td>1 (100.0%)</td>
</tr>
<tr>
<td>Morganella morganii</td>
<td>1 (1.1%)</td>
<td>1 (100.0%)</td>
<td>0 (0.0%)</td>
<td>1 (100.0%)</td>
</tr>
<tr>
<td>Candida albicans</td>
<td>1 (1.1%)</td>
<td>1 (100.0%)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*ESBL-negative MDR. UTI: urinary tract infection; ESBL: extended-spectrum β-lactamase; MDR: multidrug-resistance.

Fig. 2. Rates of initial inappropriate antibiotic administration in patients with extended-spectrum β-lactamase, ESBL-negative multidrug-resistant (ESBL-negative MDR), and non-ESBL/non-MDR organisms (42.1% vs. 20.7% vs. 2.2%, respectively; ESBL vs. non-ESBL/non-MDR, p < 0.001; ESBL-negative MDR vs. non-ESBL/non-MDR, p = 0.012). ESBL: extended-spectrum β-lactamase; MDR: multidrug-resistant.

Fig. 3. Kaplan-Meier curves to compare time intervals to appropriate antibiotic therapy among the three groups. Both patients with extended-spectrum β-lactamase (5.0 h [1.5-72.0 h]) and ESBL-negative multidrug-resistant (ESBL-negative MDR; 2.0 h [1.5-4.5 h]) organisms had a longer time to appropriate antibiotic treatment than those with non-ESBL/non-MDR organisms (2 h [1.5-3.0 h]; p < 0.001 and p = 0.032, respectively, by log-rank test). ESBL: extended-spectrum β-lactamase; MDR: multidrug-resistant.

the most commonly used agents for empirical treatments (carbapenems, n = 22; β-lactam/β-lactamase inhibitors, n = 10; β-lactam/β-lactamase inhibitor and quinolone combinations, n = 6; other combinations, n = 1), and 16.0% (15/94) of all enrolled patients initially received inappropriate antibiotics. However, the rates of initial inappropriate antibiotic administration were higher in both patients with ESBL-producing and ESBL-negative MDR organisms compared with cases with non-ESBL/non-MDR organisms (42.1 % vs. 20.7% vs. 2.2%, respectively; Fig. 2). The time to appropriate antibiotic treatment was also longer in both of the MDR groups (p < 0.001 and p = 0.033; Fig. 3). However, the type of infection (i.e., community-acquired vs. healthcare-associated vs. hospital-acquired infection) was not associated with antibiotic inappropriateness (16.4% vs. 12.0% vs. 10.9%, p = 0.737).

4) Comparison of hospital mortality

ICU and hospital mortality rates were 12.8% (12/94) and 14.9% (14/94), respectively. Patients with ESBL producers showed a higher mortality rate than the other two groups (31.6% vs. 10.3% [ESBL-negative MDR organisms] vs. 10.9% [non-ESBL/non-MDR organisms]; Fig. 4); there was a significant difference between patients with ESBL producers and other groups (p = 0.033). Among patients with E. coli isolates, the hospital mortality was 28.6% and 14.3% in those with ESBL-positive and ESBL-negative MDR isolates, respectively. However, the type of infection did not have an impact on hospital mortality (10.9% vs. 20.0% vs. 21.4%, p = 0.737).
Table 3. Clinical and laboratory variables of survivors and non-survivors

<table>
<thead>
<tr>
<th>Variables</th>
<th>Survivors (n = 80)</th>
<th>Non-survivors (n = 14)</th>
<th>p value</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr</td>
<td>73.0 (65.3-80.8)</td>
<td>73.5 (66.8-82.3)</td>
<td>0.614</td>
<td>-</td>
</tr>
<tr>
<td>Gender, M/F</td>
<td>16/64</td>
<td>1/13</td>
<td>0.435</td>
<td>-</td>
</tr>
<tr>
<td>Charlson comorbidity index</td>
<td>5.0 (4.0-7.0)</td>
<td>6.0 (4.8-8.0)</td>
<td>0.241</td>
<td>-</td>
</tr>
<tr>
<td>Laboratory findings†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematocrit, %</td>
<td>34.1 (29.1-37.9)</td>
<td>28.1 (26.1-33.2)</td>
<td>0.046</td>
<td>0.113</td>
</tr>
<tr>
<td>Lactate, mmol/L</td>
<td>3.8 (2.3-5.4)</td>
<td>4.5 (3.3-10.5)</td>
<td>0.079</td>
<td>-</td>
</tr>
<tr>
<td>BNP, pg/ml</td>
<td>236.2 (119.9-490.5)</td>
<td>1102.6 (389.0-2234.4)</td>
<td>0.001</td>
<td>0.024</td>
</tr>
<tr>
<td>Troponin I, ng/ml</td>
<td>0.03 (0.02-0.11)</td>
<td>0.13 (0.04-0.22)</td>
<td>0.074</td>
<td>-</td>
</tr>
<tr>
<td>SAPS II at admission</td>
<td>45.0 (40.0-51.8)</td>
<td>60.5 (56.3-74.8)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Prior admission within one year</td>
<td>41 (51.3%)</td>
<td>11 (78.6%)</td>
<td>0.058</td>
<td>-</td>
</tr>
<tr>
<td>Catheter-associated UTI‡</td>
<td>17 (21.3%)</td>
<td>3 (21.4%)</td>
<td>0.988</td>
<td>-</td>
</tr>
<tr>
<td>Hospital-acquired infection</td>
<td>11 (18.3%)</td>
<td>3 (21.4%)</td>
<td>0.433</td>
<td>-</td>
</tr>
<tr>
<td>Prior history of UTI within one year</td>
<td>14 (17.5%)</td>
<td>5 (35.7%)</td>
<td>0.117</td>
<td>-</td>
</tr>
<tr>
<td>Structural abnormalities or lesions</td>
<td>25 (31.3%)</td>
<td>5 (35.7%)</td>
<td>0.762</td>
<td>-</td>
</tr>
<tr>
<td>ESBL production</td>
<td>13 (16.3%)</td>
<td>6 (42.9%)</td>
<td>0.033</td>
<td>0.046</td>
</tr>
<tr>
<td>ESBL-negative MDR</td>
<td>26 (32.5%)</td>
<td>3 (21.4%)</td>
<td>0.376</td>
<td>-</td>
</tr>
<tr>
<td>Bacteremia</td>
<td>55 (68.8%)</td>
<td>10 (71.4%)</td>
<td>1.000</td>
<td>-</td>
</tr>
<tr>
<td>Inappropriate antibiotics</td>
<td>10 (12.5%)</td>
<td>5 (35.7%)</td>
<td>0.044</td>
<td>0.210</td>
</tr>
</tbody>
</table>

*Multivariate logistic regression analysis. †Other laboratory data (white blood cell count, platelet, blood urea nitrogen, bilirubin, and albumin) were not significantly associated with hospital mortality. ‡Urinary catheter for two weeks or longer. BNP: brain natriuretic peptide; SAPS: simplified acute physiology score; UTI: urinary tract infection; ESBL: extended-spectrum β-lactamase; MDR: multi-drug resistance.

Fig. 4. Hospital mortality rates in patients with extended-spectrum β-lactamase, ESBL-negative multidrug-resistant (ESBL-negative MDR), and non-ESBL/non-MDR organisms (31.6% vs. 10.3% vs. 10.9%, respectively; ESBL organisms vs. others, p = 0.033). ESBL: extended-spectrum β-lactamase; MDR: multidrug-resistant.

21.4% in community-acquired vs. healthcare-associated vs. hospital-acquired infection, respectively, p = 0.433). The length of hospital stay tended to be greater in patients with ESBL producers than in patients without ESBL producers (14.0 days [13.0-22.0 days] vs. 12.0 days [9.0-19.0 days], p = 0.061).

5) Risk factors associated with hospital mortality

In univariate analyses, Charlson comorbidity index and co-morbid illnesses were not associated with hospital mortality. However, hematocrit, brain natriuretic peptide (BNP), SAPS II, ESBL production, and inappropriate antibiotics were significant factors (Table 3). These five variables were included into the multivariate analysis (Hosmer-Lemeshow goodness-of-fit test, chi-square = 1.187, and p = 0.997; Table 3), which revealed that ESBL production was significantly associated with increased hospital mortality (odds ratio [OR], 11.547; 95% confidence interval [CI], 1.047-127.373); when the age variable was added to the model, the OR of ESBL production was 13.938 (95% CI, 1.074-180.831). However, when the variable of inappropriate antibiotic administration was excluded from the model, the OR of ESBL production increased to 21.971 (95% CI, 2.335-206.741).

6) Risk factors for ESBL production

Among the clinical and laboratory variables, prior admission within one year (p = 0.005), hospital-acquired infection (p = 0.007), and a bed-ridden state (p = 0.009) were more frequently identified in ESBL-positive patients than in ESBL-negative patients. In the multivariate model (Hosmer-Lemeshow goodness-of-fit test, chi-square = 3.119, and p = 0.682), prior admission within one year (p = 0.032) and hospital-acquired infection (p = 0.047) were significantly associated with ESBL production; however, when the age variable was added to the model, only prior admission within one year (p = 0.032) was a significant risk factor.
Discussion

This study had several findings; first, ESBL-producing and ESBL-negative MDR organisms accounted for 20.2% and 33.9%, respectively, of infections in patients admitted to the ICU for UTI sepsis. Second, both ESBL production and ESBL-negative MDR were associated with a delay in the administration of appropriate antibiotic treatment; however, only ESBL production, not ESBL-negative MDR, was an independent risk factor for hospital mortality in patients with UTI sepsis. Third, a history of hospital admission was a significant risk factor for ESBL production.

There has been an increase in the emergence of drug-resistant organisms in the past two decades, and many authors have studied the incidence and risk factors of ESBL production in patients with UTI.[7,19-21] In previous studies, several authors reported that ESBL production or MDR is associated with inappropriate antibiotic administration or an increased length of hospital stay. However, UTI is known to be associated with a low risk of mortality among patients with septicemia,[11] and the relationships between MDR organisms and increased mortality rates remain debatable.[9,19,22,23] However, because treatment options are limited in MDR infections, these infections could have a significant impact on hospital outcomes in critically ill patients, especially in the ICU setting.

Worldwide, 17.9% of \( E.\ coli \) isolates from UTI specimens are ESBL producers, and the Asia-Pacific region has the highest ESBL rate (i.e., 27.7%).[24] According to the Study for Monitoring Antimicrobial Resistance Trends (SMART) study by Lu et al.[4] China and Vietnam have the highest ESBL rates of 60%, and Singapore, Malaysia, and Thailand have rates of ~30% among isolates that cause UTI. In the present study, we found an ESBL rate of 20.2% among all isolates and 21.2% among \( E.\ coli \) isolates; these rates are similar to the Korean data from the SMART study. However, the ESBL rate among patients with \( E.\ coli \) bacteremia was higher (17.4%, 8/46) than those in previous studies.[8,20] In particular, \( P.\ mirabilis \) (42.9%) and \( K.\ pneumoniae \) (33.3%) had higher rates of ESBL production than did \( E.\ coli \) isolates. The ESBL rate among \( K.\ pneumoniae \) isolates was also higher (26%), as reported in a Taiwanese nationwide surveillance study.[25] The authors noted an increase in the rate of ESBL production among \( K.\ pneumoniae \) isolates in their ICUs. Therefore, continuous surveillance for these ESBL-producing organisms is needed among patients admitted to the ICU for UTI sepsis.

Many risk factors associated with ESBL production have been identified in previous studies,[9,12,19] including previous antibiotic use (especially fluoroquinolones), previous admission, male gender, diabetes mellitus, and recurrent UTI. In this study, we also found that prior admission within one year was a risk factor. However, some studies have indicated that inpatient infection or complicated UTI is more likely to be associated with ESBL production than is outpatient infection or uncomplicated UTI.[26,27] Therefore, healthcare practitioners should be attuned to the possibility of ESBL production in patients with UTI sepsis and/or hospital-acquired infection.

Infections caused by ESBL or MDR organisms are known to be associated with increased morbidity and mortality,[28,29] which is primarily associated with a delay in appropriate antibiotic therapy. Although we observed a higher mortality in patients with inappropriate antibiotics compared to those with appropriate antibiotics, there was no significant association in the multivariate analysis in this study. Several previous studies have shown conflicting results.[6,8,22,30] However, a significant number of elderly patients with severe illness (i.e., SAPS II) were enrolled in the present study and could have died due to underlying disease or severe illness rather than to the actual infection.

With regard to patient outcome, we reported a hospital mortality of 14.9% in the present study. Although this result is higher than those of other studies,[31,32] patient age, comorbidity, and severity of illness at ICU admission must also be considered. The previous mortality rate for patients with septic shock due to a urinary source ranged from 10% to 20%, which was lower than the rates for other common septic shock sources.[11] Other Korean studies also reported mortality rates in the range of 9.1%-25.9%.[11] In particular, Chang et al.[33] reported that \( E.\ coli \) had a lower case fatality rate than all other Gram-negative infections among patients with hospital-acquired UTI. This low mortality rate is considered to be associated with the relatively straightforward treatment for UTI. However, considering the importance of appropriate empirical treatment for severe MDR pathogenic infections, physicians should consider individual risk factors, clinical severity, and local epidemiology when making decisions about patient treatment.

Many authors have discussed ESBL production rather than MDR when studying patients with UTI. Although all ESBL producers were MDR organisms in our study, we found that only ESBL production, not ESBL-negative MDR, was significantly associated with increased mortality in the multivariate analysis. This suggests that the important prognostic factor among patients with UTI sepsis admitted to the ICU is not whether the
causal organism is MDR, but rather, whether the organism is an ESBL producer. In previous studies, Menashe et al.[34] and Kim et al.[35] determined that there was no significant association between ESBL production and mortality. However, in a meta-analysis by Rottier et al.[28] the authors reported that bacteremia caused by an ESBL producer was associated with a higher mortality than bacteremia with ESBL-negative organisms, and the higher mortality was likely to be mediated through inappropriate antibiotic therapy. However, we also found that adjusting for inappropriate antibiotic treatments decreased the OR of ESBL production, which was indicated in the study by Rottier et al. Therefore, in our study, the effect of ESBL production on hospital mortality can partially be explained by inappropriate antibiotic treatments. Additionally, we found that BNP was also significantly associated with hospital mortality. Recent studies suggested that BNP may be a powerful predictor of mortality in patients with sepsis.[36,37] Therefore, taking this factor into consideration might also provide a better prognosis for patients with UTI sepsis admitted to the ICU.

There were several limitations to this study. First, the 95% CIs for ESBL producers in the multivariate analysis were wide because the sample size was small. Second, there is a possibility of unintended bias due to the retrospective nature of the study. Third, the ESBL-negative MDR organisms were heterogeneous and may have different antibiotic resistance mechanisms. Therefore, these limitations should be considered when the results are interpreted. However, despite these limitations, our study had several major strengths. First, we collected an extensive range of patient data, including the status of indwelling urinary catheters, structural lesions in the urinary tract, and prior history of UTI. In addition, we focused only on septic patients with a severe illness diagnosis who had been admitted to the ICU.

This study determined that, although both ESBL-producing and ESBL-negative MDR organisms are associated with a delay in appropriate empirical treatments, only ESBL production, not ESBL-negative MDR, is a significant predictor of hospital mortality. Therefore, it is necessary to evaluate the possibility of ESBL-producing organisms when deciding on empirical antibiotic treatment, and ESBL production should be considered when diagnosing patients with UTI sepsis in the ICU setting.

Acknowledgements

The authors thank resident physicians and registered nurses in the ICU for their dedication to this study.

References


